{"id":145983,"date":"2025-03-10T13:53:49","date_gmt":"2025-03-10T08:23:49","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=145983"},"modified":"2025-03-10T13:53:52","modified_gmt":"2025-03-10T08:23:52","slug":"pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/","title":{"rendered":"Pharma stock jumps 3% after receiving permission to sell lung cancer treatment drug in India"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1536219237\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>This Pharma stock, which deals in the business of manufacture, distribution, and marketing of products related to pharmaceuticals, was up 3 percent after permission to sell Durvalumab in India used for the treatment of Lung Cancer.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3093350567\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Share Price Movement&nbsp;<\/strong><\/h2><p>In Monday\u2019s trading session, <a href=\"https:\/\/portal.tradebrains.in\/stocks\/ASTRAZEN\" target=\"_blank\" rel=\"noreferrer noopener\">A<strong>straZeneca Pharma India<\/strong><\/a>&#8216;s share price touched a day\u2019s high of Rs. 7,679.85, which is 2.75 percent higher. The share price reiterated from the day\u2019s high and was trading at Rs. 7,578.40, which is 1.40 percent higher than the previous closing price of Rs. 7,474 apiece. In the past year, the stock has given around 41 percent returns and outperformed the Nifty Index.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>What Happened<\/strong><\/h2><p>The company\u2019s stock was in focus after AstraZeneca Pharma India exchange filing revealed that they have received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab solution for the infusion 120 mg\/2.4 ml and 500 mg\/10 ml (Imfinzi) for an additional indication.<\/p><p>This Durvalumab is indicated for the treatment of patients with limited stage small cell lung cancer (LS-SCLC) whose disease has not progressed following the platinum-based chemoradiation therapy (CRT). This permission helps the company to market this solution in India, subject to the receipt of related statutory approvals if required.<\/p><div class=\"trade-content_5\" id=\"trade-2219202822\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Financials<\/strong><\/h2><p>In its latest filing for the quarter ending December 2024, the company reported a 43.79 percent rise in revenue, reaching Rs. 440 crore compared to Rs. 306 crore in Q3FY24. During the same period, net profit increased by 93.75 percent to Rs. 31 crore in Q3FY25, compared to Rs. 16 crore in Q3FY24.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Business segment<\/strong><\/h2><p>AstraZeneca recognises its operating revenue under the Healthcare segment as its sole segment as of the December 2024 quarter.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Company Overview&nbsp;<\/strong><\/h2><p>AstraZeneca Pharma India Limited (AZPIL), established in 1979, is a subsidiary of AstraZeneca Plc, UK. It operates in therapeutic areas like cardio-metabolism, oncology, and respiratory diseases, with manufacturing and headquarters in Bengaluru, Karnataka.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by &#8211; Santhosh S<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-643750398\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>This Pharma stock, which deals in the business of manufacture, distribution, and marketing of products related to pharmaceuticals, was up 3 percent after permission to sell Durvalumab in India used for the treatment of Lung Cancer. Share Price Movement&nbsp; In Monday\u2019s trading session, AstraZeneca Pharma India&#8216;s share price touched a day\u2019s high of Rs. 7,679.85, [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":98971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[18722,17415,22817,17414,17413,6616,948,936,3157],"class_list":["post-145983","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-astrazeneca-pharma","tag-astrazeneca-pharma-cancer-drug","tag-astrazeneca-pharma-india","tag-astrazeneca-pharma-latest-news","tag-astrazeneca-pharma-share-price","tag-pharma-stock","tag-stock-market","tag-stock-market-news","tag-stock-to-watch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock jumps 3% after receiving permission to sell lung cancer treatment drug in India - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"This Pharma stock, which deals in the business of manufacture, distribution, and marketing of products related to pharmaceuticals, was up 3 percent after permission to sell Durvalumab in India used for the treatment of Lung Cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock jumps 3% after receiving permission to sell lung cancer treatment drug in India\" \/>\n<meta property=\"og:description\" content=\"This Pharma stock, which deals in the business of manufacture, distribution, and marketing of products related to pharmaceuticals, was up 3 percent after permission to sell Durvalumab in India used for the treatment of Lung Cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-10T08:23:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-10T08:23:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/\",\"name\":\"Pharma stock jumps 3% after receiving permission to sell lung cancer treatment drug in India - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"datePublished\":\"2025-03-10T08:23:49+00:00\",\"dateModified\":\"2025-03-10T08:23:52+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"This Pharma stock, which deals in the business of manufacture, distribution, and marketing of products related to pharmaceuticals, was up 3 percent after permission to sell Durvalumab in India used for the treatment of Lung Cancer.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock jumps 3% after receiving permission to sell lung cancer treatment drug in India\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock jumps 3% after receiving permission to sell lung cancer treatment drug in India - Trade Brains Features","description":"This Pharma stock, which deals in the business of manufacture, distribution, and marketing of products related to pharmaceuticals, was up 3 percent after permission to sell Durvalumab in India used for the treatment of Lung Cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock jumps 3% after receiving permission to sell lung cancer treatment drug in India","og_description":"This Pharma stock, which deals in the business of manufacture, distribution, and marketing of products related to pharmaceuticals, was up 3 percent after permission to sell Durvalumab in India used for the treatment of Lung Cancer.","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-03-10T08:23:49+00:00","article_modified_time":"2025-03-10T08:23:52+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/","name":"Pharma stock jumps 3% after receiving permission to sell lung cancer treatment drug in India - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","datePublished":"2025-03-10T08:23:49+00:00","dateModified":"2025-03-10T08:23:52+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"This Pharma stock, which deals in the business of manufacture, distribution, and marketing of products related to pharmaceuticals, was up 3 percent after permission to sell Durvalumab in India used for the treatment of Lung Cancer.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-receiving-permission-to-sell-lung-cancer-treatment-drug-in-india\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock jumps 3% after receiving permission to sell lung cancer treatment drug in India"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=145983"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145983\/revisions"}],"predecessor-version":[{"id":145984,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145983\/revisions\/145984"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/98971"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=145983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=145983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=145983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}